Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

NextCure Q3 2026 Results: Net Loss of $6.85M, Loss Narrows

NextCure reported a net loss of $31.5 million for the nine months ended September 30, 2026, an improvement from the $46.4 million loss in the prior year period. The company's cash position decreased significantly to $8.7 million as it underwent restructuring and asset impairment charges totaling $3.0 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-6.8-8.6
EPS (diluted, $ a share)$-1.29$-3.22

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: NXTC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

NextCure, Inc.: key numbers

Share price
$6.68Close, Nov 16
Market cap
$30.6M
Shares outstanding
4.58MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from NextCure, Inc.

All →
4:01 PM ET Form 4
Insider Buying

NextCure Insider ADAR1 Capital Management LLC Buys $62.9K of Stock

ADAR1 Capital Management LLC bought 12,333 shares of NextCure, Inc. at $5.10 a share, worth $62.9K in total on Nov 11, 2026. Shares held after the trade: 750,289 (+1.7%).

Value
$62.9K
Shares
12,333
Price
$5.10
Holding change
+1.7%
Trade date
Nov 11, 2026
4:16 PM ET 8-K
M&A Deal

NextCure Signs $820M M&A Deal with Avere Therapeutics, Inc.

NextCure provided a status update on its pending merger with Avere Therapeutics, noting that the SEC has declared its S-4 registration statement effective and a stockholder vote is scheduled for December 9, 2026. The transaction is supported by $820 million in committed financing from a syndicate of healthcare investors to fund the development of Avere's lead inflammatory disease program, AVR-001.

Value
$820M
Counterparty
Avere Therapeutics, Inc.

“During the third quarter, we continued to execute on the strategic initiatives associated with our proposed merger with Avere Therapeutics. Importantly, total financing commitments supporting the proposed transaction increased to approximately $820 million from a syndicate of leading healthcare-focused and institutional investors. We believe this significant financing commitment reflects strong confidence in Avere's clinical development strategy and the potential of AVR-001, while enhancing the opportunity to create long-term value for NextCure stockholders.”

Michael Richman, President and CEO of NextCure
4:20 PM ET Form 4
Insider Buying

NextCure Insider ADAR1 Capital Management LLC Buys $18.7K of Stock

ADAR1 Capital Management LLC bought 3,662 shares of NextCure, Inc. at $5.10 a share, worth $18.7K in total on Nov 6, 2026. Shares held after the trade: 737,956 (+0.5%).

Value
$18.7K
Shares
3,662
Price
$5.10
Holding change
+0.5%
Trade date
Nov 6, 2026
8:00 AM ET 8-K
Leadership Change

NextCure Leadership Change

NextCure, Inc. announced that Chief Medical Officer Dr. Udayan Guha will be terminated effective October 31, 2026. The departure is in contemplation of the company's pending merger with Avere Therapeutics, Inc. Dr. Guha will receive severance benefits consistent with a termination without cause, including enhanced benefits if the merger closes.

7:36 PM ET Form 4
Insider Buying

NextCure Insider ADAR1 Capital Management LLC Buys $45.3K of Stock

ADAR1 Capital Management LLC bought 9,179 shares of NextCure, Inc. at $4.83 to $5.10 a share (average $4.93) in 2 transactions, worth $45.3K in total between Oct 23, 2026 and Oct 27, 2026. Shares held after the trade: 733,270 (+0.5%).

Value
$45.3K
Shares
9,179
Average price
$4.93
Holding change
+0.5%
Trade date
Oct 23, 2026 to Oct 27, 2026
4:11 PM ET 8-K
Court & Legal Update

NextCure Court & Legal Update

NextCure filed a petition under Section 205 of the Delaware General Corporation Law seeking to validate a 1-for-12 reverse stock split previously implemented in July 2025. The company is seeking court validation due to uncertainty regarding the voting standard used for the split's approval in light of recent DGCL amendments and its pending merger with Avere Therapeutics. A court hearing on the validation petition is scheduled for November 6, 2026.

Counterparty
Delaware Court of Chancery

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.